PRIMMUNE THERAPEUTICS, INC.

Profile

Company Names

PRIMMUNE THERAPEUTICS, INC.

Addresses

C/O JLABS SAN DIEGO, 3210 MERRYFIELD ROW, SAN DIEGO, CA 92121-1126

1929 EAST POINTE AVENUE, CARLSBAD, CA 92008

Phone Numbers

858-205-2281

 

Entity Type:

CORPORATION

Industry:

PHARMACEUTICALS, OTHER TECHNOLOGY

Year Incorporated:

2017

State Incorporated:

DELAWARE

Total Amount Raised:

$20,125,009.00

Number of Funding Rounds:

5
Investment Rounds
Round #
Round Open Date
Amount Raised
Total Round Size
Amount Remaining to be Raised
Securities
5
2020-10-23 
$13,000,009.00 
$24,000,008.00 
$10,999,999.00 
Equity 
4
2020-02-28 
$2,500,000.00 
$3,500,000.00 
$1,000,000.00 
 
3
2019-02-04 
$2,000,000.00 
$4,000,000.00 
$2,000,000.00 
 
2
2018-07-27 
$1,100,000.00 
$4,000,000.00 
$2,900,000.00 
 
1
2017-10-18 
$1,525,000.00 
$1,525,000.00 
$0.00 
 
People
First Name
Middle Name
Last Name
Titles
Related Companies
JAMES 
R 
APPLEMAN 
EXECUTIVE OFFICER, DIRECTOR
PRIMMUNE THERAPEUTICS, INC.
JAMES 
R. 
APPLEMAN 
EXECUTIVE OFFICER, DIRECTOR
PRIMMUNE THERAPEUTICS, INC.
TODD 
J 
HARRIS 
DIRECTOR
PRIMMUNE THERAPEUTICS, INC.
TODD 
J. 
HARRIS 
DIRECTOR
PRIMMUNE THERAPEUTICS, INC.
CHARLES 
 
MCDERMOTT 
EXECUTIVE OFFICER, DIRECTOR
RENAISSANCE LIGHTING INC   |  SUSTAINABLE SPACES INC   |  TIOGA ENERGY, INC.   |  ADVANCED ELECTRON BEAMS, INC.   |  PROJECT FROG INC   |  RECURVE, INC.   |  KALA PHARMACEUTICALS, INC.   |  AMOS SYSTEMS LLC   |  DM-DSP, LLC   |  PRIMMUNE THERAPEUTICS, INC.
SCOTT 
 
MORENSTEIN 
DIRECTOR
GEMIN X PHARMACEUTICALS INC   |  VALENCE ADVANTAGE LIFE SCIENCES FUND II, L.P.   |  CELATOR PHARMACEUTICALS INC   |  VELICEPT THERAPEUTICS, INC.   |  MOLECULAR TEMPLATES, INC.   |  ANTIOS THERAPEUTICS INC.   |  PRIMMUNE THERAPEUTICS, INC.   |  PALVELLA THERAPEUTICS, INC.
AMIR 
 
NASHAT 
DIRECTOR
PROMEDIOR INC   |  AVILA THERAPEUTICS INC   |  PERVASIS THERAPEUTICS INC   |  FATE THERAPEUTICS INC   |  BIND BIOSCIENCES INC   |  SELECTA BIOSCIENCES INC   |  POLARIS VENTURE PARTNERS VI, L.P.   |  SUN CATALYTIX CORP   |  RECEPTOS, INC.   |  POLARIS ENTREPRENEURS- FUND VII, L.P.   |  POLARIS PARTNERS VII, L.P.   |  ATYR PHARMA INC   |  AGBIOME, LLC   |  METACRINE, INC.   |  SCHOLAR ROCK LLC   |  1366 TECHNOLOGIES INC   |  SOFREGEN MEDICAL INC.   |  POLARIS ENTREPRENEURS- FUND VIII, L.P.   |  SYROS PHARMACEUTICALS, INC.   |  SCHOLAR ROCK HOLDING CORP   |  CAMP4 THERAPEUTICS CORP   |  MORPHIC HOLDING, LLC   |  FREENOME HOLDINGS, INC.   |  PRIMMUNE THERAPEUTICS, INC.   |  MORPHIC HOLDING, INC.
PAULO 
S 
RANGEL 
EXECUTIVE OFFICER, DIRECTOR
PRIMMUNE THERAPEUTICS, INC.
PAULO 
S. 
RANGEL 
EXECUTIVE OFFICER, DIRECTOR
PRIMMUNE THERAPEUTICS, INC.
ANDREW 
 
RUBINSTEIN 
DIRECTOR
OBERLAND CAPITAL HEALTHCARE LP   |  OBERLAND CAPITAL HEALTHCARE OFFSHORE LP   |  TWILIGHT CO-INVEST LP   |  PRIMMUNE THERAPEUTICS, INC.   |  QUANTBIO INNOVATIONS FUND LP   |  QUANTBIO ABSOLUTE RETURN FUND LP
Filings
Filing Date
Filing Type
Source URL
Industry Classifier
Detailed Industry
Revenue Range
Securities
First Sale Date
2020-11-06
D
Link
PHARMACEUTICALS 
 
DECLINE TO DISCLOSE 
Equity 
2020-10-23 
2020-03-17
D
Link
PHARMACEUTICALS 
 
DECLINE TO DISCLOSE 
 
2019-02-04 
2020-03-17
D
Link
PHARMACEUTICALS 
 
DECLINE TO DISCLOSE 
 
2020-02-28 
2020-03-17
D
Link
PHARMACEUTICALS 
 
DECLINE TO DISCLOSE 
 
2018-07-27 
2018-01-30
D/A
Link
OTHER TECHNOLOGY 
 
DECLINE TO DISCLOSE 
 
2017-10-18 
2017-11-08
D
Link
OTHER TECHNOLOGY 
 
DECLINE TO DISCLOSE 
 
2017-10-18 
Brokers
Broker Dealer
Broker CRD#
Recipient Name
Recipient CRD#